Qyuns Completed More Than $20 Million In Series B Financing

Accoring to China venture, Qyuns just completed more than 20 million dollars in Series B financing. This round of financing was led by Hongtai capital, and followed by Triwise. The funds will be used to recruit more professionals for the company's new drug.

Qyuns was founded in 2015, it is a research and development company for monoclonal antibody drugs for immune diseases. At present, the company is researching 6 varieties, mainly interleukin antibody drugs, of which two biosimilar drugs have entered clinical trials.

The number of patients with autoimmune diseases in China is large, and there is great market demand. Monoclonal antibodies are the most effective treatment for immune diseases. There is still great growth potential in the future for this market.

Hongtai Capital is a private equity and venture capital firm that specializes in direct and fund of funds investments through Aplus Fund and Aplus Capital.

Triwise Capital is an investment firm that focuses on venture capital and M&A business in China.